Nasdaq

Mersana Therapeutics Reports Positive Initial Phase 1 Data for Emi-Le and Receives Additional Fast Track Designation

Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...
Nasdaq

Larimar Therapeutics Reports Positive Initial Data from Nomlabofusp OLE Study for Friedreich’s Ataxia

Larimar Therapeutics reports positive results from nomlabofusp study for Friedreich’s ataxia, showing increased frataxin levels and potential clinical benefits. Larimar Therapeutics announced positive ...
Seeking Alpha

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels ...
Seeking Alpha

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs ...